toxylact
The first professional lActological database in the word
A10AB01 — Human Insulin: Academic Toxicological and Lactological Monograph
1. ATC Classification and Pharmacological Profile
ATC code A10AB01 designates insulin (human) within the Anatomical Therapeutic Chemical classification hierarchy A10 (Drugs used in diabetes), A10A (Insulins and analogues), and A10AB (Insulins and analogues for injection, fast-acting). The WHO ATC/DDD system assigns insulin (human) in this subgroup a defined daily dose of 40 units by parenteral administration; the DDD is a standardized drug-utilization metric and does not represent an individualized therapeutic dose. ATCDDD
A10AB01 principally refers to soluble (regular) human insulin, conventionally produced by recombinant DNA technology. Recombinant human insulin is structurally identical to endogenous human insulin and is a polypeptide composed of two peptide chains linked by disulfide bonds, with a molecular weight of approximately 5.8 kDa. FDA Access Data
Human insulin acts through the insulin receptor, a transmembrane receptor tyrosine kinase. Receptor activation initiates intracellular signaling that increases peripheral glucose uptake, particularly in skeletal muscle and adipose tissue, while suppressing hepatic glucose production. Insulin additionally inhibits lipolysis and proteolysis and promotes protein synthesis, thereby exerting broad anabolic metabolic effects. FDA Access Data
Following conventional subcutaneous administration, regular human insulin is classified as short-acting. Its glucose-lowering effect typically begins within approximately 30 minutes, although substantial interindividual variability occurs; maximal pharmacodynamic activity occurs later, and the duration of effect extends for several hours. The precise time-action profile depends on dose, injection site, local blood flow, physical activity, metabolic state, and other patient-specific factors. Intravenous administration produces substantially more immediate systemic activity and therefore requires close clinical monitoring. FDA Access Data
The therapeutic role of human insulin includes glycemic control in insulin-dependent diabetes and other clinical situations requiring exogenous insulin. From a lactological standpoint, human insulin is distinctive because the therapeutic molecule is identical in structure to a physiological hormone that is also naturally present in human breast milk. NCBI
2. Toxicological Profile
The toxicology of human insulin is predominantly an extension of its physiological pharmacodynamic activity. Hypoglycemia is the principal and potentially life-threatening toxic effect. It occurs when insulin activity exceeds the metabolic requirement determined by circulating glucose, carbohydrate intake, endogenous glucose production, and energy expenditure. DailyMed
Mild or moderate hypoglycemia may produce autonomic and neuroglycopenic manifestations including sweating, tremor, hunger, palpitations, dizziness, impaired concentration, behavioral alteration, visual disturbance, and weakness. Severe hypoglycemia may progress to disorientation, seizures, unconsciousness, coma, neurological injury, and death. DailyMed
Insulin overdose may additionally cause hypokalemia, because insulin stimulates movement of potassium from the extracellular compartment into cells. Severe untreated hypokalemia can result in neuromuscular dysfunction, respiratory paralysis, cardiac arrhythmias, and potentially fatal complications. This effect is particularly relevant with intravenous administration or substantial overdose. DailyMed
Other recognized adverse effects include injection-site reactions, lipohypertrophy or lipoatrophy with repeated subcutaneous administration, weight gain, edema, and hypersensitivity reactions. Severe generalized allergic reactions, including anaphylaxis, are possible but uncommon. DailyMed
In lactating women, maternal hypoglycemia deserves particular attention because postpartum insulin requirements may differ substantially from requirements during pregnancy or before conception. According to the current LactMed review, insulin requirements in women with type 1 diabetes are generally approximately 30–50% below prepregnancy doses immediately postpartum, although requirements subsequently evolve and show marked interindividual variability. Average insulin requirements during breastfeeding have been reported to remain below prepregnancy requirements, but this pattern is not uniform. NCBI
Consequently, continuation of an inadequately adjusted pregnancy insulin regimen after delivery can expose the mother to excessive insulin action. Maternal hypoglycemia is also indirectly relevant to infant safety because severe neuroglycopenia can temporarily impair the mother's capacity to safely hold, feed, or care for the infant.
3. Lactation Pharmacology and Breast-Milk Exposure
Human insulin is a normal physiological constituent of breast milk. Accordingly, the presence of insulin in milk cannot itself be interpreted as pharmaceutical contamination or as evidence of clinically significant drug exposure. LactMed reports measurable endogenous insulin concentrations in milk from healthy women as well as detectable exogenous insulin in milk from insulin-treated women. NCBI
Older experimental data involving nursing women with diabetes demonstrated increased milk insulin concentrations following intravenous administration of regular insulin, with peak milk concentrations observed approximately 30–50 minutes after administration. More recent observations also support transfer of exogenous insulin into human milk and suggest that mammary insulin transport may involve an active mechanism rather than unrestricted passive diffusion. NCBI
These findings require careful pharmacological interpretation. Milk transfer does not imply clinically meaningful systemic exposure of the breastfed infant. Human insulin is a peptide hormone and is susceptible to enzymatic degradation within the gastrointestinal tract. Its oral systemic bioavailability is extremely low. Therefore, insulin ingested by the breastfed infant does not behave pharmacokinetically like a readily absorbed small-molecule drug.
This distinction also limits the clinical utility of a conventional relative infant dose (RID) calculation. RID estimates are particularly useful when the amount of drug ingested through milk approximates potential systemic infant exposure. For insulin, however, gastrointestinal proteolysis and negligible oral bioavailability substantially dissociate the swallowed milk dose from the systemically available infant dose.
Importantly, LactMed explicitly states that mothers with diabetes who use insulin may breastfeed and that exogenous insulin is excreted into breast milk. Furthermore, recombinant human insulin has been administered enterally to preterm infants in clinical research without generating a lactation-related safety signal that would suggest orally delivered insulin represents a significant systemic hazard. NCBI
Insulin present in breast milk may also have physiological functions within the infant gastrointestinal tract. It has been investigated in relation to intestinal maturation and metabolic and immunological development. These potential physiological effects should, however, be distinguished from claims that therapeutic maternal insulin administration provides a proven additional health benefit to the infant; available evidence does not justify such an inference. NCBI
4. Effects in the Breastfed Infant and on Lactation
Current evidence provides no established pattern of clinically significant adverse effects in breastfed infants attributable to maternal therapeutic use of human insulin. LactMed reports no relevant published infant serum-level data and no established adverse-effect series attributable to insulin exposure through breast milk. NCBI
Clinically significant infant hypoglycemia caused by maternal insulin therapy through breastfeeding is not expected. Although insulin is measurable in milk, the infant's gastrointestinal degradation of the peptide and its negligible oral systemic bioavailability make a pharmacologically significant systemic glucose-lowering effect highly improbable.
Accordingly, routine monitoring of infant blood glucose solely because a breastfeeding mother is receiving human insulin is generally unnecessary in a healthy term infant. Clinical investigation remains appropriate whenever an infant develops unexplained symptoms suggestive of hypoglycemia or another metabolic disorder, but such symptoms should not automatically be attributed to maternal insulin treatment.
The effects of diabetes and insulin therapy on lactation itself require a more nuanced assessment. Physiological insulin activity is necessary for normal mammary metabolism, and adequate metabolic control supports lactogenesis. LactMed reports that good glycemic control enhances maternal serum and milk prolactin responses and can reduce delayed establishment of lactation associated with type 1 diabetes. NCBI
At the same time, observational studies have found delayed lactogenesis II more frequently among some women with diabetes requiring insulin therapy. This association should not be interpreted simplistically as a direct inhibitory pharmacological effect of injected insulin. Insulin treatment often identifies women with greater underlying metabolic disturbance, and diabetes-related metabolic control, obstetric factors, maternal characteristics, and perinatal circumstances may contribute to delayed lactogenesis. NCBI
Once breastfeeding is established, women with diabetes can maintain successful lactation. Maternal glucose requirements associated with milk production and changing postpartum insulin sensitivity nevertheless necessitate continued reassessment of insulin dosage and carbohydrate intake.
5. Lactological Safety Assessment and Clinical Recommendations
Human insulin (A10AB01) is considered compatible with breastfeeding. Maternal treatment with regular human insulin does not constitute an indication for withholding breastfeeding, interrupting lactation, discarding expressed milk, or routinely substituting formula feeding. LactMed explicitly supports nursing by mothers requiring insulin therapy. NCBI
No clinically meaningful benefit is expected from scheduling breastfeeding around individual subcutaneous injections. Even though milk insulin concentrations can vary, infant safety depends predominantly on the negligible systemic oral bioavailability of insulin rather than on complete avoidance of insulin in milk.
The major clinical priority is therefore maternal glycemic safety. Insulin requirements should be reassessed promptly after delivery and repeatedly during the evolution of lactation. Dose adjustment should be individualized according to glucose measurements, dietary intake, feeding frequency, physical activity, renal and hepatic function, and the mother's established insulin regimen. LactMed emphasizes considerable variability in postpartum requirements, making fixed empirical dose assumptions inappropriate. NCBI
Mothers should be educated about recognition and prompt treatment of hypoglycemia and should have an immediately accessible source of rapidly absorbable carbohydrate. Particular attention may be appropriate during the early postpartum period, overnight breastfeeding, periods of reduced caloric intake, changes in breastfeeding frequency, increased physical activity, illness, or other circumstances that alter insulin requirements.
Continuous glucose monitoring or frequent capillary glucose measurements may be useful according to the mother's diabetes-management plan. Severe or recurrent maternal hypoglycemia warrants reassessment of insulin dosing, meal timing, glucose targets, and other contributory factors.
No routine infant laboratory surveillance is required solely because of maternal human insulin therapy in a healthy breastfed infant. Additional clinical vigilance can reasonably be applied to premature, medically unstable, or metabolically vulnerable infants, although human insulin itself remains pharmacologically unlikely to produce systemic toxicity through breast milk.
Finally, product concentration and formulation must be considered separately from lactational compatibility of the insulin molecule. Medication errors involving insulin concentration or confusion between insulin preparations can cause severe maternal toxicity. Such administration hazards concern maternal treatment safety and should not be conflated with milk-mediated infant exposure. DailyMed
6. Conclusion
Human insulin classified as A10AB01 is a short-acting injectable insulin structurally identical to endogenous human insulin. Its principal toxicological hazard is excessive pharmacological activity resulting in maternal hypoglycemia; substantial exposure may also cause clinically important hypokalemia. Other adverse effects include local injection reactions, lipodystrophy, weight gain, edema, and rare systemic hypersensitivity.
Its lactological profile is highly favorable. Insulin is naturally present in human breast milk, and exogenously administered human insulin can also reach milk. Nevertheless, the presence of insulin in breast milk does not translate into clinically important systemic infant exposure because insulin is a peptide subject to gastrointestinal degradation and has negligible oral bioavailability. Current LactMed guidance supports breastfeeding during maternal insulin therapy. NCBI
No established evidence indicates clinically significant hypoglycemia or other toxicity in breastfed infants resulting from therapeutic maternal human insulin administration. Consequently, breastfeeding interruption, milk disposal, dose-to-feed separation, and routine infant glucose monitoring are not required solely on the basis of maternal A10AB01 therapy.
The principal lactation-associated clinical consideration is instead the changing maternal insulin requirement after delivery. Insulin needs commonly fall substantially in the immediate postpartum period and may remain altered during breastfeeding, with considerable individual variability. Careful glucose monitoring and individualized dose adjustment are therefore essential to minimize maternal hypoglycemia while maintaining adequate glycemic control. NCBI
Overall, A10AB01 human insulin is compatible with breastfeeding and represents a well-established glucose-lowering therapy during lactation, with the principal safety emphasis placed on maternal metabolic management rather than clinically significant drug exposure of the breastfed infant.



